BioSpace News Archive

Phyla announced the release of results from a clinical study for its Phortify Probiotic Serum containing the brand’s flagship probiotic live phage.

Adroit Surgical LLC announced that Dubai Corporation For Ambulance Services will use the Vie Scope® for intubation in all their ambulances.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Raymond James 42nd Annual Institutional Investors conference on March 1, 2021 at 11:40am Eastern Time / 8:40am Pacific Time.

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a strategic collaboration with Fox Chase Cancer Center in Philadelphia for the PGDx elio™ plasma resolve liquid biopsy panel.

Pear Therapeutics Announces Publication of Economic Analysis Showing Cost-Effectiveness of reSET-O ® in Treating Opioid Use Disorder reSET-O ® is the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for patients with opioid use disorder (OUD).

Company expands portfolio of SARS-CoV-2 testing solutions with rapid antigen test benchmarked against gold standard RT-PCR

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer, and other indications, today announced that Stephen S. Yoder, President and Chief Executive Officer of Pieris, is scheduled to participate in a GI Oncology and Pancreatic Cancer panel discussion at the Cowen 41st Annual Healthcare Conference

Recognition honors those companies who understand the importance of leading, making hard but values-based decisions, and their overall commitment to integrity

Virpax has begun the Investigational New Drug (“IND”) enabling studies of Envelta™ for Virpax to support Virpax’s future application for clearance from the FDA to initiate its first-in-human (“FIH”) clinical trials.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced it has partnered with Amplity Health in connection with the anticipated U.S. launch of Brexafemme (ibrexafungerp)